Posts

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for Intermediate AMD at ARVO 2026

EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies